Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: Sept. 29, 2024
Language: Английский
European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: 994, P. 177387 - 177387
Published: Feb. 15, 2025
Language: Английский
Citations
1
Acta Pharmaceutica Sinica B, Journal Year: 2025, Volume and Issue: 15(2), P. 1070 - 1083
Published: Jan. 23, 2025
Ischemic stroke (IS) is a globally life-threatening disease. Presently, few therapeutic medicines are available for treating IS, and rt-PA the only drug approved by US Food Drug Administration (FDA) in US. In fact, many agents showing excellent neuroprotection but no blood flow-improving activity animals have not achieved ideal clinical efficacy, while thrombolytic drugs improving flow without limited their wider application. To address these challenges meet huge unmet need, we designed identified novel compound AAPB with dual effects of cerebral improvement. significantly reduced infarction neural function deficit tMCAO rats, pMCAO IS rhesus monkeys, as well displayed exceptional safety profiles pharmacokinetic properties rats dogs. has now entered phase I trials fighting China.
Language: Английский
Citations
0
ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 12, 2025
Acute ischemic stroke (AIS) is associated with a high mortality rate and poor prognosis, lack of effective therapeutic drugs for post-thrombolytic treatment. MicroRNA-based gene therapy promising approach treating AIS, but its clinical application has been limited due to challenges, such as targeting efficiency, unsatisfactory stability, inadequate cellular uptake. In this study, we successfully developed microRNA-targeted delivery system based on the tetrahedral framework nucleic acid (tFNA). This nanodelivery system, guided by stroke-homing peptides, effectively targeted delivered miRNA124 hemisphere. With assistance tFNA, efficiently entered cells exerted effects. Additionally, it promoted transformation microglia from pro-inflammatory M1 phenotype anti-inflammatory M2 phenotype, reducing neuronal apoptosis and, ultimately, decreasing infarct size rate. These findings present strategy treatment AIS.
Language: Английский
Citations
0
Neuroscience, Journal Year: 2025, Volume and Issue: 570, P. 95 - 109
Published: Feb. 19, 2025
Language: Английский
Citations
0
Molecular Biotechnology, Journal Year: 2025, Volume and Issue: unknown
Published: March 3, 2025
Language: Английский
Citations
0
S S Korsakov Journal of Neurology and Psychiatry, Journal Year: 2025, Volume and Issue: 125(3), P. 77 - 77
Published: March 21, 2025
Objective. To evaluate the effect of Cerebrolysin on hazard dynamics hemorrhagic transformation (HT) and identify optimal anticoagulation therapy (AT) resumption timing in stroke patients, stratified by Hemorrhagic Transformation Index (HTI). Material methods. A post hoc survival analysis CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions. The intervention group (IG, n=91) received intravenous thrombolysis (IVT) standard care, while control (CG, n=147) IVT care alone. Additionally, a validation cohort (VC, n=248) from an observational study was analyzed. Patients were into low-risk (HT=0), high-risk (HTI=1—4), very-high-risk (HTI=5—8, VC only) groups. Symptomatic HT any within 14 days post-stroke defined as failure events. Hazard modeled using Gompertz parametric approach, threshold (0.6% per day) estimating safe AT timing. Results. significantly reduced risk symptomatic (HR 0.245; 95% CI 0.072—0.837; p=0.02) 0.543; 0.297—0.991; p=0.032). compounding peaked day 1 persisted through 7—10 (HTI=5—8). In mitigated levels to 2, compared 3—5 CG VC. hazardous period extended 10 HTI=5—8. (HTI=0), remained below 1, no measurable impact HT. Conclusion. may be safely resumed 48 h (HTI=5—8) without mitigates effect, reduces risk, facilitates earlier, safer (HTI=1—4) 2 post-stroke, supporting its role personalized management.
Language: Английский
Citations
0
Clinical Hemorheology and Microcirculation, Journal Year: 2025, Volume and Issue: unknown
Published: April 17, 2025
Objective: In this study, we investigated the effects of hydrogen sulfide (H 2 S) and sonic hedgehog (SHH) on proliferation, autophagy, apoptosis human microvascular endothelial cells (HCMEC/D3). We also explored regulatory relationship between cystathionine-β-synthase (CBS) SHH pathway. Method: Human microglia (HMC3) were stimulated under hypoxia to secrete H S proteins, which then co-cultured with HCMEC/D3 cells. The was by inhibiting CBS or pathways. Vascular growth factor (VEGF) levels in culture medium detected using ELISA, while via a micro method. mRNA hypoxia-inducible 1α (HIF-1 α), VEGF, Beclin-1, light chain 3 (LC3), caspase-3 RT-PCR. Protein CBS, SHH, extracellular regulated kinase 1/2 (ERK1/2), phospho-ERK1/2 (P-ERK1/2), LC3, Caspase-3 determined western blot. Results: results indicated that HIF-1α expression increased HMC3 hypoxic conditions but did not change when either signaling pathway suppressed. secretion during hypoxia, both proteins being up-regulated. inhibition resulted decreased HMC3. whereas is inhibited, level affected. found enhance P-EKR1/2, decreasing Conclusion: promotes proliferation regeneration regulating protein alleviating injury.
Language: Английский
Citations
0
Medicina, Journal Year: 2025, Volume and Issue: 61(5), P. 828 - 828
Published: April 30, 2025
Background and Objectives: Acute limb ischemia (ALI) is a life-threatening vascular emergency that requires immediate intervention to restore perfusion prevent loss or mortality. Management strategies primarily include thrombolysis surgical revascularization, each with distinct risks benefits. This review evaluates compares the outcomes of revascularization in ALI management, emphasizing their efficacy, safety, patient selection criteria. Materials Methods: A systematic was conducted adherence PRISMA guidelines, analyzing data from 15 studies, including randomized controlled trials large retrospective analyses, encompassing over 3500 patients varying demographics clinical presentations. Study quality assessed using Cochrane risk bias tool Newcastle–Ottawa Scale. Results: Thrombolysis, utilizing agents such as urokinase recombinant tissue plasminogen activator (rt-PA), demonstrated salvage rates up 90% acute cases, 30-day mortality 4–6%. It particularly effective embolic occlusions short symptom durations. However, bleeding complications associated were reported 47% cases. Conversely, remains crucial for those advanced contraindications thrombolysis, offering reliable restoration but higher perioperative morbidity, especially older significant comorbidities. Recent advancements, hybrid approaches combining catheter-directed percutaneous mechanical thrombectomy, have shown promise improving by reducing procedure times enhancing clot resolution. Conclusions: While are effective, optimizing key challenge. Future research should focus on refining treatment algorithms, investigating novel thrombolytic agents, expanding role minimally invasive techniques improve long-term while mitigating reperfusion injuries.
Language: Английский
Citations
0
American Journal of Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: May 19, 2025
Language: Английский
Citations
0
Molecular Diversity, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 5, 2024
Language: Английский
Citations
2